PDAC
25 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer (NCT05355298) | Amplia Therapeutics Limited | 2022-05-31 |
| 68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma (NCT05275985) | Peking Union Medical College Hospital | 2022-03-01 |
| A Prospective Registry for Patients at High-Risk for Pancreatic Cancer (NCT06151223) | Mayo Clinic | 2021-07-13 |
| Pancreatic Cancer Recurrence in the Netherlands (NCT04605237) | UMC Utrecht | 2014-01-01 |
| Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma (NCT07573215) | Revolution Medicines, Inc. |
Track PDAC automatically
Every clearance here is in the API, with alerts when new ones post.